y Clinical Trial Studies and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions. Patients who participate in Excell’s clinical trial studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of psychiatric or medical conditions. We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating. Financial compensation may be available to those who qualify and complete visits for clinical trial studies at Excell. Clinical Trial Studies Available: Sponsor: Alto Neuroscience Protocol Number: ALTO-100-201 Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-70 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table Sponsor Website: https://www.altoneuroscience.com/ _____________________________________________________________________________________________ Sponsor: Alto Neuroscience Protocol Number: ALTO-100-201 (Decentralized) Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? No Age: 18-70 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table Sponsor Website: https://www.altoneuroscience.com/ ______________________________________________________________________________________________ Sponsor: Alto Neuroscience Protocol Number: ALTO-100-201 (Decentralized) Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? No Age: 18-70 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table Sponsor Website: https://www.altoneuroscience.com/ ____________________________________________________________________________________________ Sponsor: Janssen Research & Development, LLC Study Name: Ventura Study Protocol Number: 67953964MDD3001 Summary: The Ventura study is a placebo-controlled study evaluating the safety and efficacy of Aticaprant used as adjunctively treatment to an antidepressant. The Ventura study is 13 weeks with 9 study visits in Oceanside, CA. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-74 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1 Sponsor Website: https://www.janssen.com/belgium/rd-janssen ______________________________________________________________________________________________ Sponsor: Neumora Therapeutics Protocol Number: NMRA-335140-301 Summary: The NMRA-335140-301 study is a placebo-controlled study evaluating the safety and efficacy of NMRA-335140 in participants with current depressive symptoms. The study is 16 weeks with 11 scheduled study visits in Oceanside, CA. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-65 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1 Sponsor Website: https://neumoratx.com/ __________________________________________________________________________________________ Sponsor: Axsome Therapeutics Protocol Number: AXS-05-MDD-401 Summary: The AXS-05-MDD-401 study is an active-controlled study of AXS-05 for the prevention of relapse of depressive symptoms. The study is initially 10 weeks with 14 visits in Oceanside, CA with the possibility of a 26-week placebo-controlled extension. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-65 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT04019704?term=AXS-05&rank=2 Sponsor Website: https://www.axsome.com/ Clinical Trial Studies Available: Sponsor: Sunovion Pharmaceuticals Protocol Number: SEP361-226 Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder. Eligibility Criteria: Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18 to 65 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table Sponsor Website: Clinical Trial Studies Available: Sponsor: Neurocrine Study Name: Erudite Study Protocol Number: NBI-1065844-CIAS2023 Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-50 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1 Sponsor Website: https://www.neurocrine.com/ _____________________________________________________________________________________________ Sponsor: Neurocrine Study Name: Journey Study Protocol Number: NBI-98854-ATS3019 Summary: The Journey study is evaluating the safety, efficacy, and tolerability of Valbenazine as Adjunctive or add on treatment in subjects with schizophrenia. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18 and older Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05110157?term=NBI-98854-ATS3019&draw=2&rank=1 Sponsor Website: https://www.neurocrine.com/ ______________________________________________________________________________________________ Sponsor: Reviva Pharmaceuticals Study Name: Recover Study Protocol Number: RVP-30-001 Summary: The Recover study is evaluating the safety and efficacy of Brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-65 Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05184335?term=RVP-30-001&rank=1&tab=table Sponsor Website: https://revivapharma.com/ _____________________________________________________________________________________________ Sponsor: Click Therapeutics, Inc. Study Name: Convoke Study Protocol Number: CT-155-R-001 Summary: The Convoke study is evaluating the safety and efficacy of two digital therapeutics as an adjunctive or add on treatment to patients with negative symptoms of schizophrenia. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18 and older Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05838625?term=CT-155-R001&rank=1&tab=table Sponsor Website: https://www.clicktherapeutics.com/ ______________________________________________________________________________________________ Sponsor: Recognify Life Sciences Study Name: Recognify Study Protocol Number: C07-03-02 Summary: The Recognify study is a placebo-controlled study evaluating the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18-55 Clinicaltrials.gov Link: https://classic.clinicaltrials.gov/ct2/show/record/NCT05686239 Sponsor Website: https://www.recognify.life/ Clinical Trial Studies Available: Sponsor: Biohaven Pharmaceuticals Study Name: Biohaven Study Protocol Number: BHV4157-302 Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder. Eligibility Criteria: Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 18 to 65 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1 Sponsor Website: Clinical Trial Studies Available: Sponsor: AbbVie Name: Periscope Study Protocol Number: 3110-305-002 Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 12-17 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2 _____________________________________________________________________________________________ Sponsor: AbbVie Name: Kaleidoscope Study Protocol Number: M21-201 Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Atogepant for the preventive treatment of episodic migraine in children and adolescence. Eligibility Criteria Key Inclusion Criteria: Key Exclusion Criteria: Patient Time Reimbursed? Yes Patient Travel Reimbursed? Yes Age: 12-17 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05711394?term=M21-201&draw=2&rank=1Interested in participating in Clinical Trial Studies?
Active Clinical Trial Studies
Clinical Trial Studies available to participants
Learn more about Clinical Trial Studies